TQA-2225

N/A

Report date: 2025/02/25 16:56:34

Base Information

Drug NameTQA-2225
Drug Alias NameRecombinant human FGF21 Fc fusion protein (Anyuan Pharmaceutical)重组人FGF21-Fc融合蛋白 (安源医药)AP-025TQA2225TQA-2225
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionFibroblast growth factor 21 agonists
TargetsFibroblast growth factor 21
Therapy Area/IndicationsHypertriglyceridemiaMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAnyuan Pharmaceutical Technology (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupAnyuan Pharmaceutical Technology (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsHypertriglyceridemiaMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A